The Triple-Hormone-Receptor Agonist Retatrutide for Obesity was a phase 2 trial which examined retatrutide at various doses and dose-escalation regimens in patients with obesity [60]. Here, NR4A1 is linked to obesity due to melanocortin 4 receptor deficiency.